FDA ex­pands ap­proval of Agios' Tib­so­vo; As­traZeneca's long-act­ing di­a­betes drug se­cures US nod

→ Tib­so­vo is Agios’ first whol­ly-owned prod­uct, sec­ond ap­proved ther­a­py and the last drug that founder David Schenkein saw across the fin­ish line be­fore hand­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER